Top Markets
#1 Celer Network Celer Network +49.10%
#2 Gravity Gravity +24.44%
#3 Galxe Galxe +23.88%
#4 ICON ICON +13.39%
#5 MemeCore MemeCore +13.25%
#6 Cartesi Cartesi +12.87%
#7 Zilliqa Zilliqa +10.95%
#8 Genius Genius +10.65%
#9 Ontology Gas Ontology Gas +9.33%
#10 CyberDEX CyberDEX +7.13%
Coin of the day
Celer Network Celer Network
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Rang in Aktien #40225
Fusion Antibodies plc operates as a contract research organization (CRO),... Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United Kingdom, broader Europe, and North America. Its comprehensive suite of offerings encompasses monoclonal antibody discovery and advancement, antibody sequencing and engineering, and a distinct platform for antibody humanization and rational affinity maturation. Additionally, Fusion Antibodies provides recombinant protein expression, stable cell line development, and cGMP-compliant scale-up services. Clients span the pharmaceutical, biotechnology, and diagnostic sectors. Notably, the company maintains a collaborative partnership with Celonic AG. Established in 2000, Fusion Antibodies plc is headquartered in Belfast, United Kingdom.
Aktienkurs
$0.1559364
Zuletzt synchronisiert: 2026-09-18
Marktkapitalisierung
$195.17K
Veränderung (1 Tag)
6.60%
Veränderung (1 Jahr)
-30.91%
Land
GB
Handel Fusion Antibodies plc (FAB)

Kategorie

Healthcare
Operative Marge für Fusion Antibodies plc (FAB)
Operative Marge zum September 2026 TTM: -118.73%
Laut den neuesten Finanzberichten und dem Aktienkurs von Fusion Antibodies plc beträgt die aktuelle operative Marge (TTM) -118.73%. Am Ende des Jahres 2024 lag die operative Marge bei -201.41%.
Historie der operativen Marge von Fusion Antibodies plc von 2013 bis 2026
Operative Marge zum Jahresende
Jahr Operative Marge ändert
2026 (TTM) -118.73% 31.15%
2025 -90.53% -55.05%
2024 -201.41% 106.24%
2023 -97.66% 251.80%
2022 -27.76% -16.16%
2021 -33.11% 15.77%
2020 -28.60% -58.63%
2019 -69.14% -3,080.17%
2018 2.32% -64.90%
2017 6.61% 253.48%
2016 1.87% -117.22%
2015 -10.86% -34.26%
2014 -16.52% -85.86%
2013 -116.84% 0.00%
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Operative Marge Differenz der operativen Marge Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -100.33%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -100.24%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -98.74%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.57% -100.22%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.